Prostate Studies
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

A Phase 3 Randomized, Placebo-Controlled Double-Blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
More Information

A Single-Arm, Phase II Study to Evaluate the Safety and Efficacy of VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
More Information

An Open-Label, Multicenter, Expanded Access Program for MPDL3280A in Patients with PD L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
More Information

Comprehensive Genetic Characterization of Intraprostatic Chronic Inflammation and Prostate Cancer in
African American Men


ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
More Information

Taste in Prostate Cancer

A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic
Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial
More Information

A Phase II, Randomized, Open-Label, Multicenter Study in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Who Have PRIMary Resistance to Abiraterone Acetate or Enzalutamide Treatment Comparing the Anit-Tumor Effect of CABazitaxel to Alternative Androgen Receptors (AR) Targeted Therapy
More Information

A Phase II Open-Label, Parallel Group Study of Abiraterone Acetate Plus Prednisone in African-American and Caucasian Men with Metastatic Castration-Resistant Prostate Cancer
More Information

Alliance A031201
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
More Information

GU 115
A Double-Blinded, Placebo-Controlled, Randomized Phase II Trial of Enzalutamide With or Without the PI3 Kinase/m TOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

More Information

UAB 1336
A Phase 2 Trial of Carfilzomib for Metastatic Castration-Resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors
More Information

A Phase I Study of a Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 in Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (mCRPC)
More Information

Radium-223 Alpha Emitter Agent in Safety Study in mCRPC Population for Long-Term Evaluation
More Information

Sotio SP005
A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
More Information


A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer (PREDICT)
More Information

BAY 16544

A Randomized Open-label Phase IIa Study Evaluating the Efficacy and Safety of Radium-223 Dichloride in Combination with Abiraterone Acetate or Enzalutamide in Subjects with CRPC Who Have Bone Metastases
More Information

RTOG 0924
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy In Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
More Information

TUHC 07/25/13 - Genetics of Prostate Cancer

BAY 15396

A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
More Information

SWOG S1216

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
More Information

1430 Tulane Ave, New Orleans, LA 70112